The story of copyright's flagship drug presents a interesting case for investors in the drug sector. While initially a blockbuster success, generating vast sums, the patent lapse and the subsequent entry of cheaper alternatives have considerably impacted earnings. This raises questions about the ongoing viability of analogous medication projects an